EPTN marks a decade of European particle therapy collaboration and sets its next priorities
After 10 years, EPTN is shifting its focus toward prospective registries, adaptive therapy, harmonised QA and stronger clinical evidence.
After 10 years, EPTN is shifting its focus toward prospective registries, adaptive therapy, harmonised QA and stronger clinical evidence.
In 22 patients, salvage HDR brachytherapy produced 40.5% five-year relapse-free survival but 18% developed grade ≥3 GU toxicity.
AI reduced six-OAR contouring workflow from about 20 to 9.5 minutes, while spinal cord and brainstem differences remained clinically relevant.
Rectal retractor use lowered rectal D2cc and was associated with fewer grade ≥2 vaginal adverse events without reducing target coverage.
Across 3,817 patients, severe toxicity was uncommon with RT plus ADCs, except for a radiation-necrosis signal with intracranial RT and T-DM1.
In randomized phase II SOFT Preop, five-fraction SBRT better preserved patient-reported quality of life than 28-fraction chemoradiotherapy. Pathological nodal positivity did not differ significantly, but oncologic noninferiority was not established.
In a small phase II study, induction and concurrent paclitaxel with RT, usually followed by surgery, achieved 82.5% two-year PFS in cutaneous angiosarcoma. Grade 3+ acute and late toxicity occurred in 58% and 32%, respectively.
NRG-HN009 found no reduction in overall acute grade 3-4 toxicity with weekly versus three-weekly cisplatin during definitive head and neck RT. Toxicity profiles differed, and neither phase II cohort met the criteria to proceed to phase III.
In PACE-A, moderate-to-severe erectile dysfunction at 5 years affected 44% of SBRT respondents vs 89% after prostatectomy. The patient-reported difference was significant, but analyses were as treated and follow-up questionnaires were incomplete.
In MDT-BRIDGE, patients who became unresectable during neoadjuvant durvalumab plus chemotherapy could transition to definitive CRT and consolidation durvalumab, with 85% 12-month PFS in a small selected cohort.
TRIDENT found no OS benefit from starting TTFields during RT/TMZ rather than at maintenance in newly diagnosed glioblastoma. Median OS was 17.7 vs 17.5 months. A post hoc MGMT-methylated subgroup signal remains exploratory.
Photon STAR plans kept an echocardiographic probe below 1 Gy without compromising target coverage, although low-dose spread increased modestly.
Ten-year lung SBRT survivors developed rare airway, chest-wall and pericardial toxicities, while no local failures occurred beyond year 10.
After neoadjuvant ADT, 40% of MRI-visible prostate lesions disappeared and remaining lesions shrank substantially more than the prostate gland.
Tocilizumab, atezolizumab and 24 Gy/3-fraction FSRT produced only a 3.4% objective response rate in recurrent glioblastoma.